Cephalon — Proxy Contest (April 2011)
53 slides from Cephalon's proxy contest presentation, Apr 28, 2011
Slide 1: Valeant's Offer to Acquire Cephalon
Valeant’s Offer to Acquire Cephalon April 28, 2011 0
Slide 2: Forward-looking Statements
Forward-looking Statements Certain statements made in this communication may constitute forward-looking statements of Valeant, including, but not limited to, statements regarding our offer to purchase Cephalon, financing related to the proposed transaction, our consent solicitation process or our in
Slide 3: Agenda
Agenda 1. Summary of Key Questions for ISS 2. Cephalon Stockholders Have the Right to Decide 3. A Full Accounting of Cephalon’s Track Record and Risky Future 4. A Fair Analysis of Cephalon’s Value 5. How Cephalon Stockholders Can Unlock Value 2
Slide 4: Summary of Key Questions for ISS
Summary of Key Questions for ISS 3
Slide 5: Key Questions for ISS
Key Questions for ISS What Is Valeant Hearing from Stockholders? What Do Analysts Think? Why Now? Is Valeant Just Being Opportunistic? How Does Valeant Value the Pipeline? Is Valeant’s Offer Full and Fair Value? Why Does Valeant Believe it is the Best Bidder? 4
Slide 6: What is Valeant Hearing From Stockholders?
What is Valeant Hearing From Stockholders? We have spoken with over 60 stockholders of Cephalon and have heard the following themes: Right time for CEPH to be sold given recent performance, management change, and risk associated with new long-term strategy Want VRX to begin diligence to see how much
Slide 7: What Do Analysts Think? (1/2)
What Do Analysts Think? (1/2) VRX offer meets or exceeds 95% of analyst price targets 73 78 45 48 5455 55 57 57 58 58 59 60 60 65 65 66 67 70 72 $59.50 Median Barclays Jefferies Caris Sanford MS* Hapoalim enheimer* Piper Susq. Bernstein* Baird Collins P Morgan ckingham BAML Agricole UBS Stifel JMP S
Slide 8: What Do Analysts Think? (2/2)
What Do Analysts Think? (2/2) Firm Comments Post-VRX Offer Jefferies “CEPH Owners Should Take $73” “We view the deal terms as reasonable and would recommend selling Barclays CEPH shares here” “Likelihood of competing bids or a price bump is relatively low” JP Morgan “The offer presents an upside cas
Slide 9: Why Now? (1/2 — VRX Perspective)
Why Now? (1/2 — VRX Perspective) Revenues from Provigil over the next 12 months: ~$1.1bn Provigil gross margin 90% Provigil profit before tax (minimal if any OpEx) = ~$1.0bn Potential synergies: ~$300m Cash spent on non-core acquisitions: ? Assuming recent cash spend history, at least $1.3bn of pre-
Slide 10: Why Now? (2/2 — Wall Street Example)
Why Now? (2/2 — Wall Street Example) Morgan Stanley Equity Research’s DCF illustrates CEPH’s declining value: CEPH FCF Forecast ($mm) Perpetuity Growth WACC: 2011E 2012E 2013E 2014E 2015E Rate: 9.5% $754 $437 $355 $507 $390 -4% Current Value of $55 / share (including $11 / share in cash value) Using
Slide 11: Is Valeant Just Being Opportunistic?
Is Valeant Just Being Opportunistic? We believe Cephalon was trading at fair value when we made our offer Share price incorporated negative sentiment due to no solution for the patent cliff, recent pipeline failures and a high-risk pipeline Share price at time of offer was in the same range as the t
Slide 12: How Does Valeant Value the Pipeline?
How Does Valeant Value the Pipeline? Our offer does include our assessment of the value of the pipeline It is important to note that, regardless of the potential market for CEPH’s product, its value has to be probability adjusted and the cash flows discounted back Cephalon’s analysts describe CEPH’s
Slide 13: Is Valeant's Offer Full and Fair Value?
Is Valeant’s Offer Full and Fair Value? VRX’s Offer Encompasses Both the Near-Term Cash Flows and Longer Term Pipeline $4 $10 $2 $11 $38 $24 $33 $73 $21 $28 $22 $22 $23 Bernstein($1) Susquehanna Caris and Co Morgan Stanley Valeant’s Offer Next Five Years Terminal Value / Pipeline Net Cash / (Debt) V
Slide 14: Why Does Valeant Believe it is the Best Bidder?
Why Does Valeant Believe it is the Best Bidder? The pharmaceutical industry is generally trying to avoid patent cliffs and many companies are dealing with their own patent issues ~$1.5bn of Cephalon’s 2010 sales (54% of total) will be off-patent in the next 5 years Few companies have the execution e
Slide 15: Cephalon Stockholders Have the Right to Decide
Cephalon Stockholders Have the Right to Decide 14
Slide 16: Cephalon Stockholders Have the Right to Decide
Cephalon Stockholders Have the Right to Decide Cephalon’s Board does not want to give you, the stockholders, the right to maximize the value of Cephalon now Cephalon’s Board has rejected Valeant’s $73.00 offer Cephalon’s Board also refused to let Valeant conduct due diligence, which could lead to a
Slide 17: CEPH's Board Has Not Created Value for CEPH Stockholders
CEPH’s Board Has Not Created Value for CEPH Stockholders Stockholders have lost value over the last 5 years Time Period 3 months 6 months 1 year 2 year 5 year Share Price CAGR (22.8%) (13.5%) (19.1%) (7.1%) (0.5%) Track record of R&D failures Cephalon has been unable to find a solution to impending
Slide 18: CEPH's Future Performance is Expected to Decline Substantially
And CEPH’s Future Performance is Expected to Decline Substantially Based on third-party (IBES) consensus estimates, financial performance is declining rapidly: Revenues are expected to fall by 20% from 2011-2013 EPS is expected to fall by 42% from 2011-2013 Nearly $100mm of monthly revenue will go o
Slide 19: Valeant's Offer Provides Compelling and Certain Value
Valeant’s Offer Provides Compelling and Certain Value for CEPH Stockholders Our offer delivers compelling and certain value now $73 per share all-cash offer, with opportunity for more after diligence Eliminates the substantial risk associated with developing and commercializing CEPH’s pipeline Repor
Slide 20: A Full Accounting of Cephalon's Track Record and Risky Future
A Full Accounting of Cephalon’s Track Record and Risky Future 19
Slide 21: CEPH's Use of Cash Flows Has Destroyed Stockholder Value
CEPH’s Use of Cash Flows Has Destroyed Stockholder Value Have Stockholders Benefited Cephalon’s Presentation From Those Cash Flows? Since the end of 2000, CEPH share price has declined by 7% Operating margin below peers Negligible cash returned to stockholders ($34mm in last 5 years) Declining futur
Slide 22: Where is CEPH's Return on Investment?
Where is CEPH’s Return on Investment? Capital Returned to Key Investments for Growth (5 yrs) Stakeholders (5 yrs) $125MM $34MM $4.7 BN 5 Year Result $590MM $2.0 BN Share price declined by 2.3% 2 No solution for Provigil patent cliff $2 .0 BN Earnings expected to fall sharply with no clear timeline f
Slide 23: CEPH Has Historically Acquired Primarily Marketed Products
CEPH Has Historically Acquired Primarily Marketed Products Product Peak Historical Sales Year of US Comments ($ mm) Launch Developed and launched by another company in Provigil 1,124 1998 France in 1994 Acquired in 2000 post-approval Actiq 632 1993 Alternative formulation of a product approved in th
Slide 24: CEPH Strategy has Shifted to Buying Developmental R&D Assets
In the Past Few Years, CEPH Strategy has Shifted to Buying Developmental R&D Assets Lead Product(s) Development Company Total Size1 Year Stage Chemgenex $217m 2010 / 2011 Phase III Gemin X 525 2011 Phase I / Phase II Mesoblast2 350 2010 Phase II Mepha 590 2010 Marketed products BioAssets 43 2009 / 2
Slide 25: CEPH Does Not Have a Track Record of R&D Success
CEPH Does Not Have a Track Record of R&D Success CEPH’s Recent Pipeline Failures Nuvigil Dec-2010: FDA rejected attempt for new Jet Lag indication after “positive” Phase III trial Jun-2010: Primary endpoint not met in Phase II study for adjunctive therapy in adults with schizophrenia Cinquil Nov-200
Slide 26: Wall Street Analysts Raised Serious Concerns Regarding CEPH's R&D Strategy
Wall Street Analysts Raised Serious Concerns Regarding CEPH’s Risky R&D Strategy Firm Comments Post-VRX Offer “We believe that [Cephalon’s] VC like approach to more speculative biotech Barclays opportunities is difficult to understand and should be discounted substantially” (2/14/11) “Since most of
Slide 27: CEPH Pipeline has Known Issues
CEPH Pipeline has Known Issues Barclays and Morgan Stanley Performed In-depth Reviews of CEPH’s Pipeline Earlier this Year Mesoblast Stem Cells “We believe the magnitude of investment is unlikely to generate a positive return” (BAR) “FDA has never approved new stem cell therapies other than stem cel
Slide 28: VRX Believes CEPH is Destroying Stockholder Value
VRX Believes CEPH is Destroying Stockholder Value CEPH has known for years that it needs to replace Provigil sales and has been unable to do it VRX believes that CEPH has pursued more risky investments as it was unable to grow through its existing business model CEPH does not have a track record of
Slide 29: Independent Sources Project Provigil and Treanda Sales Will Drop 80% by 2016
Independent Sources Project that Sales from CEPH EPH’s Largest Products, Provigil and Treanda, Will Drop 80% by 2016 $1 ,800 Provigil Treanda $1,600 $1,400 $1,200 $1,000 $800 $600 $ 400 $200 $0 2010A 2011E 2012E 2013E 2014E 2015E 2016E 28 Source: EvaluatePharma
Slide 30: Independent Sources Predict a Steep Revenue Decline for CEPH
Independent Sources Predict a Steep Revenue Decline for CEPH 2006-2010A Revenue CAGR: 13% $ 3,500 55.0% 2011E-2013E Revenue CAGR: (10%)* 2010A Operating Margin: 36% $3,000 2013E Operating Margin: 24%* 45.0% $2,500 35.0% millions) Operating $2,000 $ es ( 25.0% Mar Revenu $1,500 gin (%) 15.0% $1,000 5
Slide 31: Independent Sources Predict Earnings Will Decline Even More Rapidly
Due to Cost Structure, Independent Sources Predict Earnings Will Decline Even More Rapidly... $9.00 2006-2010A EPS CAGR: 14% $8.00 2011E-2013E EPS CAGR: (24%)* $7.00 $6.00 Share $5.00 Per Earnings $4.00 $3.00 $2.00 $1.00 $0.00 2006A 2007A 2008A 2009A 2010A 2011E 2012E 2013E Source: Red color denotes
Slide 32: A Fair Analysis of Cephalon's Value
A Fair Analysis of Cephalon’s Value 31
Slide 33: Valeant Offer is Fair and Full Value
Valeant Offer is Fair and Full Value Decline in stock price over time reflective of pipeline uncertainty and loss of stockholder value EPS is expected to fall by 42% from 2011-2013 Issued $1,620 million in equity and equity-linked securities Multiple pipeline failures in the past two years Top-tier
Slide 34: Unaffected Cephalon Share Price Reflects Actual Decline in Fundamental Value
Unaffected Cephalon Share Price Reflects Actual Decline in Fundamental Value $80 Reported rumors of sale process $70 e (USD) VRX makes Pric offer public Closing $60 Cephalon Inc 2-Year High 2-Year Median $50 Apr-2009 Aug-2009 Dec-2009 Apr-2010 Aug-2010 Dec-2010 Apr-2011 Daily from 08-Apr-2009 to 08-
Slide 35: Biotechnology Transaction Precedents are Not Comparable
Biotechnology Transaction Precedents are Not Comparable CEPH included biotech premiums in its presentation, which are not comparable to CEPH Biotech premiums are typically much higher than other sectors due to biotech’s growth expectations Even other specialty pharma “peers” are not as relevant sinc
Slide 36: Investors Do Not Value Cephalon Like a High-Growth Biotech Company
Investors Do Not Value Cephalon Like a High-Growth Biotech Company IBES Consensus EPS 2012 P / E Multiples Growth Rate Large Pharma Index 4.8% 9.5x Specialty Pharma Peers 10.8% 10.9x High-Growth Biotech Index 38.4% 32.5x Cephalon is trading at 10.3x 2012 EPS (IBES) despite expectation for rapid earn
Slide 37: Valeant Believes Cephalon's Claims Are Unrealistic
Valeant Believes Cephalon’s Claims Are Unrealistic Cephalon’s Claims Our Perspective CEPH pipeline has significant near- to CEPH is asking stockholders to ‘trust’ them that the next five years mid-term commercial value will be better than the last five No proven success with experimental drugs to su
Slide 38: Why is VRX Willing to Pay Full Value for CEPH at $73.00 per Share?
Why is VRX Willing to Pay Full Value for CEPH at $73.00 per Share? Transaction consistent with Valeant strategy Operating model that is lower cost Unique set of synergies Partnering R&D assets with natural owners Combined company presents significant opportunities Maximize organic growth and cash fl
Slide 39: Cephalon is Not Letting Stockholders Decide
Cephalon is Not Letting Stockholders Decide Cephalon does not want to give you, the stockholders, the right to make your own decision Cephalon’s Board has rejected Valeant’s $73.00 offer Cephalon’s Board also refused to let Valeant conduct due diligence, which could lead to a higher offer Cephalon’s
Slide 40: Valeant has Nominated a Highly Qualified Group of Independent Nominees
Valeant has Nominated a Highly Qualified Group of Independent Nominees Exceptional slate of highly qualified and well-respected professionals Right combination of skills and experience Strong Management and Corporate Governance experience Extensive expertise in the healthcare and pharmaceuticals ind
Slide 41: Valeant's Nominees
Valeant’s Nominees Healthcare/ Corporate Name Management Finance Legal Pharma Governance Santo J. Costa Former President and COO of Quintiles Abe Friedman Former Global Head of BlackRock’s Corporate Governance and Proxy Voting Richard H. Koppes Former General Counsel and Interim CEO of CalPERS Lawre
Slide 42: Our Board Slate Is Experienced in Evaluating the Key Aspects of the Offer
Our Board Slate Is Experienced in Evaluating the Key Aspects of the Offer Excellence in Corporate Governance Abe Friedman (Former Global Head of BlackRock’s Corporate Governance and Proxy Voting) Richard Koppes (Winner of the National Association of Corporate Directors Lifetime Achievement Award) Jo
Slide 43: Timing is Critical for Valeant
Timing is Critical for Valeant VRX believes a substantial amount of CEPH’s equity value is represented by cash flows in the next 12 months Provigil produces ~$100m of sales / month, but will start to be replaced by generics in <12 months Near term patent cliff mean 42% of earnings are expected to be
Slide 44: Consent Solicitation Timeline and Next Steps
Consent Solicitation Timeline and Next Steps Record Date: April 8, 2011 Mailed consent solicitation materials on April 22 VRX’s deadline is May 12, 2011 to receive requisite consents If we have a majority, we will try to move ahead with an acquisition; if not, we will move on Owe it to both VRX and
Slide 45: CEPH Stockholders Have a Right to Choose
CEPH Stockholders Have a Right to Choose VRX is offering CEPH stockholders $73 in cash for their shares and more if diligence warrants an increased price CEPH’s Board and management have rejected our efforts to negotiate a transaction and VRX believes their interests are not aligned with stockholder
Slide 46: Appendix A
Appendix A Wy VALEANT
Slide 47: Valeant Pharmaceuticals Overview
Valeant Pharmaceuticals Overview Focused, multinational specialty pharma company Specialty Pharma (U.S., Canada, Australia, New Zealand) Dermatology, Neurology and Other Branded Generics — Central Europe (Poland, Serbia, Hungary, Czech Republic) Branded Generics — Latin America (Mexico, Brazil) Dive
Slide 48: Strong Execution Track Record
Strong Execution Track Record Valeant Management Team Performance** USD 740% price adjusted increase $70 in companies under current management team (Feb 2008 $60 to today) $55.33 Consistently exceeded $50 quarterly expectations $44.92 USD)$40 Total returned to stockholders via repurchases: Price ($3
Slide 49: Management's Successful M&A Track Record
Management’s Successful M&A Track Record Aton Pharma Laboratories Dr. Renaud Biovail/Valeant Merger PharmaSwiss Blaufarma Private Formula International Bunker Reckitt Benckiser (Australia Suncare Products) Cholestagel Refissa Coria Labs Tecnofarma Delta Ultravate DermaTech Vital Science Dow Pharmace
Slide 50: Appendix B
Appendix B Wy VALEANG
Slide 51: Nominee Biographies
Nominee Biographies Mr. Santo J. Costa. Mr. Costa has served as a director of Labopharm Inc. since March 2006 and Chairman of the Board since May 2006. Since June 2007 he has been Of Counsel with Smith, Anderson, Blount, Dorsett, Mitchell and Jernigan, L.L.P., of Raleigh, North Carolina, specializin
Slide 52: Nominee Biographies
Nominee Biographies Mr. Lawrence N. Kugelman. Mr. Kugelman is a healthcare consultant and private investor. Mr. Kugelman has served on the Board of Directors of Coventry Health Care, Inc., a managed care organization (Chairman of Audit Committee), since August 1992 and was a director of LabOne, Inc.
Slide 53: Valeant's Offer to Acquire Cephalon
Valeant’s Offer to Acquire Cephalon April 28, 2011 54